Cabergoline

What is Cabergoline?

Cabergoline is a selective dopamine D2 receptor agonist medication belonging to the ergot alkaloid derivative class of pharmaceuticals. It is classified under ATC code E10, which encompasses medications used in endocrinology for pituitary and hypothalamic disorders. Cabergoline was first developed in Italy in the 1980s and has since become a widely prescribed treatment for conditions characterized by elevated prolactin levels in the blood.

The drug works by stimulating dopamine receptors in the anterior pituitary gland, effectively suppressing the secretion of prolactin hormone. Unlike some earlier dopamine agonists, Cabergoline demonstrates superior tolerability, fewer side effects, and longer-lasting effects due to its extended half-life of 63-69 hours. This pharmacokinetic profile allows for less frequent dosing, typically twice weekly, making it more convenient for patient compliance compared to its predecessors.

Cabergoline is available in oral tablet formulations and is marketed under various brand names worldwide, with Dostinex being one of the most recognized trade names. The medication has become the preferred choice for managing prolactin-secreting pituitary adenomas and other hyperprolactinemic conditions due to its efficacy profile and safety record in long-term clinical use.

⚙️ Mechanism of Action

Cabergoline exerts its therapeutic effects through selective agonism of dopamine D2 receptors located on lactotroph cells in the anterior pituitary gland. Dopamine is a natural inhibitory neurotransmitter that regulates prolactin secretion; when dopamine levels are insufficient or dopamine receptor function is impaired, prolactin levels elevate. By acting as a dopamine mimetic, Cabergoline restores the inhibitory tone on lactotroph cells, thereby reducing prolactin synthesis and secretion into the bloodstream. This mechanism is particularly effective because Cabergoline demonstrates high selectivity and affinity for D2 receptors compared to other dopamine receptor subtypes.

• Binds with high affinity to dopamine D2 receptors on pituitary lactotroph cells, with minimal affinity for D1 receptors
• Suppresses prolactin release by restoring dopaminergic inhibition of the anterior pituitary gland
• Exhibits long-acting effects due to extended tissue retention and slow elimination from the body
• May reduce tumor size in prolactin-secreting adenomas through direct anti-proliferative effects on tumor cells
• Maintains stable prolactin suppression with twice-weekly dosing due to prolonged receptor occupancy

🏥 Medical Uses & Indications

Cabergoline is primarily indicated for the management of hyperprolactinemic disorders, conditions characterized by abnormally elevated serum prolactin concentrations. These conditions can result from pituitary adenomas, idiopathic hyperprolactinemia, or secondary causes such as medication-induced increases. The medication is also used in reproductive medicine and endocrinology to manage the clinical consequences of elevated prolactin, including menstrual irregularities, infertility, and sexual dysfunction.

Primary Indications

• Prolactinoma (prolactin-secreting pituitary adenoma) - both microadenomas and macroadenomas
• Idiopathic hyperprolactinemia - elevated prolactin without identifiable pituitary adenoma
• Restless legs syndrome (RLS) - particularly effective for moderate to severe cases when other treatments have failed
• Medication-induced hyperprolactinemia - such as from antipsychotic or metoclopramide use
• Management of infertility associated with hyperprolactinemia in both men and women
• Treatment of galactorrhea (inappropriate lactation) and menstrual dysfunction secondary to prolactin excess

Secondary / Off-label Uses

• Acromegaly - adjunctive therapy when used in combination with somatostatin analogs or growth hormone antagonists
• Parkinson's disease - as dopaminergic replacement therapy in advanced stages
• Pituitary apoplexy - supportive management of hormone-secreting adenomas during acute events
• Prevention of ovarian hyperstimulation syndrome (OHSS) in assisted reproductive technology protocols

💊 Dosage & Administration

Cabergoline dosing is individualized based on the specific indication, patient response, and tolerance profile. Treatment typically begins at a low dose with gradual titration upward at weekly or bi-weekly intervals until therapeutic prolactin suppression is achieved or adverse effects become limiting. The extended half-life of Cabergoline allows for convenient dosing schedules, usually administered twice weekly on non-consecutive days. Tablets should be taken with food to minimize gastrointestinal upset, though food does not significantly affect absorption.

Important: Always follow your prescriber's instructions. Dosages vary by patient weight, age, and condition. Regular monitoring of serum prolactin levels and clinical response is essential during dose adjustment phases. Maximum recommended doses should not exceed 16 mg per day in divided doses.

⚠️ Side Effects

Common Side Effects (>10% of patients)

• Nausea and gastrointestinal upset - typically mild and often diminishes with continued treatment or dose reduction
• Headaches - ranging from mild tension-type headaches to migraine-like presentations
• Dizziness or lightheadedness - particularly upon standing, related to orthostatic blood pressure changes
• Fatigue and asthenia - generalized weakness or lack of energy reported by some patients
• Constipation - resulting from dopaminergic effects on gastrointestinal motility
• Breast tenderness or galactorrhea rebound - paradoxically occurring during dose adjustments

Less Common Side Effects (1-10%)

• Psychiatric effects - including depression, anxiety, or mood changes requiring monitoring
• Hot flushes and sweating - thermoregulatory disturbances potentially related to hypothalamic dopamine effects
• Abdominal pain or dyspepsia - gastrointestinal discomfort necessitating dose adjustment
• Palpitations or arrhythmias - cardiac rhythm disturbances reported in susceptible individuals
• Edema and weight gain - fluid retention or metabolic alterations in some patients

Rare but Serious Side Effects

• Cardiac valvulopathy - restrictive valvular disease potentially occurring with long-term use, requiring baseline and periodic echocardiographic monitoring particularly at doses exceeding 2-3 mg daily
• Pleural effusion and pulmonary fibrosis - serious pulmonary complications reported with prolonged therapy, necessitating respiratory function assessment
• Psychosis or severe psychiatric decompensation - particularly in patients with underlying psychiatric vulnerability or predisposition

🔄 Drug Interactions

Cabergoline can interact with various medications through multiple mechanisms including dopaminergic competition, cytochrome P450 metabolism, and additive pharmacological effects. Understanding these interactions is critical for safe prescribing, particularly in patients requiring polypharmacy. Most interactions are not absolute contraindications but require dose adjustment, monitoring, or timing separation between administrations.

• Antipsychotic medications (haloperidol, risperidone, olanzapine) - these dopamine antagonists directly antagonize Cabergoline's mechanism of action and may reduce efficacy significantly
• Metoclopramide and domperidone - dopamine antagonist antiemetics that can counteract prolactin suppression achieved by Cabergoline
• Monoamine oxidase inhibitors (MAOIs) - may potentiate dopaminergic effects and increase risk of hypertensive crisis or serotonin syndrome
• Hormonal contraceptives and hormone replacement therapy - may affect prolactin levels and require Cabergoline dose adjustment for optimal control
• Ergot alkaloid derivatives (ergotamine, methysergide) - concurrent use with Cabergoline increases risk of ergotism and peripheral vasoconstriction
• CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin) - may increase Cabergoline plasma concentrations and adverse effects by inhibiting hepatic metabolism

🚫 Contraindications & Warnings

• Known hypersensitivity or allergy to Cabergoline or ergot alkaloid derivatives - represents an absolute contraindication due to risk of anaphylaxis and serious allergic reactions
• Uncontrolled hypertension - Cabergoline can affect blood pressure regulation and should be avoided without adequate antihypertensive control
• History of cardiac valvulopathy or fibrotic disorders - baseline echocardiography is mandatory before initiating therapy, especially at higher doses
• Porphyria cutanea tarda and other hepatic porphyrias - Cabergoline may precipitate severe porphyric crises in susceptible individuals
• Pregnancy and nursing - while Cabergoline is sometimes used to manage prolactinomas during pregnancy, it should only be used when benefits outweigh risks and under specialist supervision; it is contraindicated in nursing mothers as it suppresses lactation
• Severe hepatic impairment - dose reduction is required due to hepatic metabolism of Cabergoline

Medical Disclaimer: This information is for educational purposes only. Always consult a qualified healthcare professional before starting, stopping, or changing any medication.

❓ Frequently Asked Questions

Is Cabergoline safe for long-term use?

Cabergoline has demonstrated safety and efficacy in long-term clinical use spanning decades, with many patients successfully maintained on therapy for 10+ years. However, long-term safety requires regular monitoring. Baseline and periodic cardiac evaluation via echocardiography is recommended, particularly when doses exceed 2-3 mg per week, to screen for valve disease. Serum prolactin levels and clinical symptom assessment should be monitored regularly. Most patients tolerate Cabergoline well chronically, though some may experience diminishing efficacy over time, necessitating dose adjustment. The benefits of long-term prolactin suppression in managing prolactinomas and hyperprolactinemia typically outweigh potential risks when appropriate monitoring is maintained.

Can Cabergoline be taken with food?

Yes, Cabergoline can be taken with or without food. However, administering Cabergoline with food, particularly with a light meal, may reduce gastrointestinal side effects such as nausea, which is one of the most common adverse reactions. Food does not significantly impair the absorption or bioavailability of Cabergoline, so taking it with meals is a reasonable strategy for improving tolerability. Consistent administration timing helps maintain steady plasma concentrations and may improve patient adherence to the prescribed dosing schedule.

What should I do if I miss a dose?

If a dose of Cabergoline is missed, it should be taken as soon as remembered unless it is almost time for the next scheduled dose. In that case, skip the missed dose and resume the regular dosing schedule without doubling doses. Since Cabergoline has a long half-life of 63-69 hours, a single missed dose is unlikely to result in significant clinical consequences or prolactin level elevation. However, consistently missing doses may result in loss of prolactin suppression and recurrence of symptoms. Setting reminders or using pill organizers can help prevent missed doses, particularly important for patients taking the medication twice weekly.